The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma.
Silvia MeziAndrea BotticelliSimone ScagnoliGiulia PomatiGiulia FisconFederica De GalitiisFrancesca Romana Di PietroSofia VerkhovskaiaSasan AmirhassankhaniSimona PisegnaGiovanna GentileMaurizio SimmacoBjoern GohlkeFilippo De BraudMarina Chiara GarassinoPublished in: Cancers (2023)
DDIs emerged as a critical issue for the risk of treatment-related cardiovascular toxicity. Our findings support the utility of DDI assessment in melanoma patients treated with BRAF/MEK inhibitors.